ARTICLE | Strategy
Expanding shots on goal
July 27, 2009 7:00 AM UTC
Post-acquisition, compounds from Medarex Inc. (NASDAQ:MEDX) will comprise 40% of Phase I and 33% of Phase II compounds being developed by Bristol-Myers Squibb Co. (NYSE:BMY) to treat cancer and autoim...